
Opinion|Videos|June 13, 2024
Treatment Transitions: Exploring Clinical Responses to Ruxolitinib Monotherapy for Atopic Dermatitis Management
Author(s)Lawrence Eichenfield, MD
An expert in the management of dermatological conditions shares insights on managing atopic dermatitis patients, discussing the real-world effectiveness and physician satisfaction with ruxolitinib cream as a treatment option, as well as its adoption among healthcare providers.
Advertisement
Episodes in this series

Video content above is prompted by the following question(s):
- How do the study findings align with your own clinical experiences and observations in managing patients with atopic dermatitis (AD)?
- What additional information would you find valuable to assess the real-world effectiveness of ruxolitinib cream in managing AD, beyond what was presented in the study methodology?
- Please comment on how physician satisfaction has influenced the adoption and integration of ruxolitinib cream in clinical practice.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Switching from Biologics to Upadacitinib Yields Progressive Improvements in Moderate to Severe AD
2
New Consensus Defines Remission, Disease Activity in Atopic Dermatitis
3
How Dermatologists Can Incorporate GLP-1 Receptor Agonists Into Psoriasis Care
4
Referral Barriers Persist in Advanced Cutaneous Squamous Cell Carcinoma Care
5














